N/A N=28 Increasing Documentation and Disclosure of Sickle Cell Trait Status: An Implementation Science Approach
Sickle Cell Trait
Primary: Acceptability — 11; 8; 11; 8 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Early Phase 1 N=22 Red Cell Half Life Determination in Patients With and Without Sickle Cell Disease
Sickle Cell Disease · Sickle Cell Anemia
Primary: Mean Red Blood Cells Lifespan in Participants — 64.1; 113.4; 126.0; 123.7 day — p=<0.001
N/A N=145 Evaluation of Low-cost Techniques for Detecting Sickle Cell Disease and β-thalassemia in Nepal and Canada
Sickle Cell Disease · Sickle Cell Trait · Beta-Thalassemia
Primary: Sensitivity, Specificity, Positive Predictive Value and Negative Predictive Value — 96.6; 100; 0; 91.3 percentage
Early Phase 1 N=17 A Dose-Finding Study of AG-348 in Sickle Cell Disease
Sickle Cell Disease
Primary: Number Participants With Most Common Reported Drug Related Adverse Events — 6; 3; 3 Participants
N/A N=112 Sickle Cell Anemia WE CARE
Sickle Cell Disease
Primary: Number of Emergency Department (ED)/Acute Care Visits — 0; 1 number of visits
N/A N=237 Preventing Acute Chest Syndrome by Transfusion Feasibility Study
Sickle Cell Disease
Primary: Acute Chest Syndrome — 11; 11; 22; 85 participants
Phase 3 N=30 Stem Cell Transplantation for Sickle Cell Anemia
Sickle Cell Disease
Primary: Number of Participants With Graft Failure — 3 Participants
N/A N=212 Examining Cognitive Function and Brain Abnormalities in Adults With Sickle Cell Disease
Anemia, Sickle Cell
Primary: Wechsler Adult Intelligence Scale (WAIS)-III Performance IQ — 90.6; 95.9 Points on a scale — p=0.008
Phase 1 N=26 An Assessment of Prasugrel on Healthy Adults and Sickle Cell Adults
Anemia, Sickle Cell
Primary: Area Under the Plasma Concentration-Time Curve (AUC) From Time of Dosing Through the Sampling Time of the Last Quantifiable Concentration [AUC(0-tlast)] for Prasugrel's…
Phase 2 N=30 Evaluating the Safety and Effectiveness of Bone Marrow Transplants in Children With Sickle Cell Disease (BMT CTN 0601)
Sickle Cell Disease
Primary: Percentage of Participants With Event-Free Survival (EFS) — 76; 69 percentage of participants
Phase 2 N=7 A Study Evaluating the Safety and Efficacy of LentiGlobin BB305 Drug Product in β-Thalassemia Major (Also Referred to as Transfusion-dependent β-Thalassemia [TDT]) and Sickle Cell Disease
Beta-Thalassemia Major · Sickle Cell Disease
Primary: Number of Treated Participants With Successful Neutrophil and Platelet Engraftment — 3; 4; 3; 4 Participants
Phase 1 N=39 Adenosine 2A Agonist Lexiscan in Children and Adults With Sickle Cell Disease
Sickle Cell Disease
Primary: Dose Limiting Toxicities as a Measure of Whether Infusional Lexiscan is Safe in Individuals With SCD. — 1; 0; 0; 0 number of DLT
Phase 2 N=95 Haploidentical Bone Marrow Transplantation in Sickle Cell Patients (BMTCTN1507)
Sickle Cell Disease
Primary: Percentage of Participants With Two-Year Post-Transplant Event Free Survival (EFS) — 88.0; 79.3 Percentage of Participants
Early Phase 1 N=5 RHD Genotype Matched Red Cells for Anti-D
Sickle Cell Disease · Anti-D Antibodies
Primary: Anti-D Recurrence — 0; 5 Participants
Phase 3 N=196 Silent Cerebral Infarct Transfusion Multi-Center Clinical Trial
Sickle Cell Anemia · Stroke
Primary: Recurrence of an Infarct, Defined as a Stroke or a New or Enlarged Silent Cerebral Infarct — 2.0; 4.8 infarct recurrence per 100 person years
Phase 2 N=100 A Study of IMR-687 in Adult Participants With Sickle Cell Anemia (Homozygous HbSS or Sickle-β0 Thalassemia)
Sickle Cell Disease
Primary: Number Of Participants With Treatment-emergent Adverse Events (TEAEs) And Serious Adverse Events (SAEs) — 12; 24; 18; 23 Participants
Phase 2 N=62 Prasugrel Versus Placebo in Adult Sickle Cell Disease
Sickle Cell Anemia
Primary: Percentage of Participants With Hemorrhagic Events Requiring Medical Intervention During the Treatment Duration — 0; 0 percentage of participants
Phase 1 N=4 A Phase 1 Study of Continuous Intravenous L-citrulline During Sickle Cell Pain Crisis or Acute Chest Syndrome
Sickle Cell Disease
Primary: Number of Participants With Adverse Events — 4 Participants
N/A N=1,906 European Sickle Cell Disease Cohort - Hydroxyurea
Sickle Cell Disease
Primary: % of Patient-years With Malignancies — 0.001 % patient-years
Phase 2 N=109 Effectiveness of Arginine as a Treatment for Sickle Cell Anemia
Anemia, Sickle Cell
Primary: Gardos Channel Activity — -0.0342; 0.0043; 0.1076 mmol/10^13 cells x min — p=0.080
N/A N=73 Evaluation of Spectra Optia Red Blood Cell Exchange in Sickle Cell Patients
Sickle Cell Disease
Primary: Mean Ratio Actual Fraction of Cells Remaining (FCRa; as Measured by Post-Procedure % HbS) to the Predicted Fraction of Cells Remaining (FCRp; as Predicted by the Spectra…
N/A N=51 Cardiovascular Complications of Sickle Cell Disease
Sickle Cell Disease
Primary: MRI Parameter - LVEDVi, mL/cm2 (Measured Using Method of Disks, Controls Serve as Normal Ranges) — 124.0; 78.7 mL/cm2 — p=0.0039
N/A N=120 Decision Aid for Therapeutic Options In Sickle Cell Disease
Sickle Cell Disease · Sickle Cell Anemia · Hemoglobin SS
Primary: Acceptability of Decision Aid Education Assessed by the Acceptability Survey — 3; 3; 3; 3 units on a scale
N/A N=59 COVID-19 Vaccine Response in Sickle Cell Disease
Sickle Cell Disease · COVID-19
Primary: Antibody Response to COVID-19 Vaccine in Persons With Sickle Cell Disease — 32.155 units per mL
Phase 2 N=29 HSCT For Patients With High Risk Hemoglobinopathies Using Reduced Intensity
Sickle Cell Disease · Beta Thalassemia-Major
Primary: Number of Participants With Sustained Cell Engraftment of Donor Cells — 29 Participants
Phase 2 N=46 Fixed Dose Flavonoid Isoquercetin on Thrombo-Inflammatory Biomarkers in Subjects With Stable Sickle Cell Disease
Sickle Cell Disease
Primary: Mean Change in the Plasma Soluble P-selectin Level — 0.74; 0.10 ng/ml — p=0.64
Phase 1 N=11 Aspirin Prophylaxis in Sickle Cell Disease
Sickle Cell Disease
Primary: Number of Serious Adverse Events — 6; 9; 0; 0 events
N/A N=91 Microvascular Blood Flow in Sickle Cell Anemia
Sickle Cell Disease · Sickle Cell Anemia
Primary: Microvascular Blood Flow Rate Change — 1.09; 0.86 Ratio of change
Phase 2 N=32 A Phase 2 Study of the Effects of 6R-BH4 in Subjects With Sickle Cell Disease
Sickle Cell Disease
Primary: Number of Subjects With Treatment Emergent Adverse Events (TEAEs) — 27; 18; 20; 15 Participants
Phase 2 N=70 L-Glutamine Therapy for Sickle Cell Anemia and Sickle ß0 Thalassemia
Sickle Cell Anemia · Thalassemia
Primary: Number of Occurrences of Painful Sickle Cell Crises — 4.5; 10.8 Crisis — p=0.076